Immix Biopharma, INC Schedule 13G passive stakes

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has reported beneficial ownership of 5.6% of Immix Biopharma, Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group plc has reported a 13% beneficial ownership stake in Immix Biopharma, Inc. through its various investment management subsidiaries.

Janus Henderson Group plc has reported beneficial ownership of 4,802,002 shares, representing 9.1% of Immix Biopharma, Inc.'s common stock, as of March 31, 2026.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, disclosing beneficial ownership of 3.3% of Immix Biopharma, Inc. common stock as of March 31, 2026.

Millennium Management LLC and affiliated entities have reported a 5.3% beneficial ownership stake in Immix Biopharma, Inc. common stock.

Saturn V Capital Management LP and Xiaoying Tian have disclosed a 6.97% beneficial ownership stake in Immix Biopharma, Inc., totaling 3,693,585 shares.

Janus Henderson Group plc has reported a 7.4% beneficial ownership stake in Immix Biopharma, Inc. common stock through its various asset managers.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, reporting a 0% beneficial ownership stake in Immix Biopharma, Inc., indicating a complete divestment of their previous holdings.